December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.